Stay updated with breaking news from Amy Mahery. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Lead program, Berubicin, successfully passed pre-planned interim futility analysis milestone with recommendation from DSMB to proceed without modification in potentially pivotal GBM studyBerubicin study enrollment completed; Topline data expected in first half of 2025Clinical progress represents important steps towa...
CNS Pharmaceuticals Reports Full Year 2023 Financial Results and Highlights ...
Over my 20-plus years in the industry, I have witnessed incredible growth in many therapeutic areas, and I’m excited to see neuroscience taking...
15.08.2022 - Early launch data for VTAMA (tapinarof) with approximately 14,000 prescriptions written by more than 3,000 unique prescribers in initial eleven weeks of launch shows strong demand for first topical novel chemical entity for plaque psoriasis in 25 ...
Early launch data for VTAMA® (tapinarof) with approximately 14,000 prescriptions written by more than 3,000 unique prescribers in initial eleven weeks of...